When used alongside
standard chemotherapy agents daunorubicin and cytarabine in a treatment - resistant AML model, 99.7 percent of cancer cells were killed.
Not exact matches
According to the study authors, the results are especially impressive because half of the patients had just finished treatment with the
standard class of
chemotherapy agents — fluoropyrimidines (e.g. 5 - fluorouracil [5 - FU] or capecitabine [Xeloda]-RRB- but had failed to benefit from them.
The vaccine was tested in a preliminary clinical trial and used with
standard chemotherapy and an immune - boosting
agent.
It is hoped that combining PD - 1 / PD - L1 monoclonal antibodies with
standard chemotherapies or novel hematologic
agents may help improve outcomes.
Lead author Professor Ledermann, professor of medical oncology at the UCL Cancer Institute and a Cancer Research UK grantee, said: «A well - tolerated anti-tumour
agent that could be used for months or perhaps years as maintenance therapy after
standard chemotherapy could be a big step forward and ultimately extend survival.
To combat the nation's third deadliest cancer, the phase 1b / 2 open - label study will explore the combination of
standard chemotherapy and two immunotherapy
agents: an anti-PD-1 checkpoint inhibitor and a novel antibody targeting CD40, a protein that when activated can drive the immune system to attack tumors.